Q3 EPS Forecast for Marker Therapeutics Raised by Analyst

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Equities researchers at Brookline Capital Markets boosted their Q3 2026 earnings per share estimates for Marker Therapeutics in a report released on Saturday, August 15th. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn ($0.07) per share for the quarter, up from their prior forecast of ($0.44). The consensus estimate for Marker Therapeutics’ current full-year earnings is ($1.17) per share. Brookline Capital Markets also issued estimates for Marker Therapeutics’ Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($0.65) EPS and FY2027 earnings at ($1.57) EPS.

Several other equities analysts have also recently weighed in on MRKR. Weiss Ratings cut Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 6th. HC Wainwright reaffirmed a “buy” rating on shares of Marker Therapeutics in a research report on Wednesday, May 20th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $10.00.

Marker Therapeutics Price Performance

Marker Therapeutics stock opened at $1.15 on Wednesday. Marker Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $2.46. The firm has a fifty day moving average price of $1.31 and a two-hundred day moving average price of $1.41. The firm has a market cap of $19.17 million, a price-to-earnings ratio of -2.80 and a beta of 1.50.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.16. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 53.33%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in MRKR. Osaic Holdings Inc. grew its holdings in shares of Marker Therapeutics by 16.5% during the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after purchasing an additional 13,340 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Marker Therapeutics by 16.4% in the fourth quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock valued at $184,000 after purchasing an additional 17,400 shares in the last quarter. Jane Street Group LLC bought a new position in Marker Therapeutics in the second quarter worth $33,000. LPL Financial LLC boosted its stake in Marker Therapeutics by 41.7% during the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after buying an additional 24,500 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Marker Therapeutics in the 3rd quarter valued at $25,000. Institutional investors and hedge funds own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.